Skip to main content
. Author manuscript; available in PMC: 2015 May 20.
Published in final edited form as: Blood Lymphat Cancer. 2014 Jun 3;2014(4):15–27. doi: 10.2147/BLCTT.S49780

Figure 3.

Figure 3

Elotuzumab enhanced both ex vivo expanded NK cell-mediated, and to a lesser extent, resting NK cell-mediated killing of autologous myeloma cells in a standard 4-hour 51Cr release assay.

Abbreviations: E:T ratio, effector:target ratio; ENK, expanded natural killer cells; NK, natural killer; RNK, resting natural killer cells.